The FDA has approved Pfizer’s respiratory syncytial virus (RSV) vaccine for older adults, just a few weeks after a rival shot from GSK became the first to be cleared in the US. Pfizer’s ...

GSK's vaccine has just hit the mark in a phase 3 trial, and the company is preparing regulatory filings seeking approval for use in older adults in an attempt to stay ahead of Pfizer and other RSV ...

Life science companies developing bird flu vaccines are gaining attention as the avian influenza subtype H5N1 becomes an increasing concern. The United States is in the midst of an H5N1 bird flu ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Funding for this work has been provided by GSK. Editorial assistance was provided by ... Considerations for a Respiratory ...

Life science companies developing bird flu vaccines are gaining attention as the avian influenza subtype H5N1 becomes an ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

American leadership of vaccination efforts in developing countries has evaporated, along with USAid funding for the programs. New Covid-19 variants are being discovered monthly and an array of other ...

Blue Lake Biotechnology to Present Safety and Immunogenicity Data for its RSV Intranasal Vaccine Candidate at the 13th International RSV Symposium Blue Lake Biotechnology, Inc., a clinical-stage ...